Michael (Mike) Perry is currently CEO and Director of Avita Medical Ltd. and Managing Director at venture capital firm BioScience Managers Pty Ltd. Previously (2012-2017) he served as SVP, Global BD&L, Chief Scientific Officer, Cell & Gene Therapy Unit, and Global Head, Cellular Therapy at Novartis AG. He served as a Venture Partner with Bay City Capital from 2004 to 2012. He also previously served as CEO of Pharsight Corp., SyStemix Corp,, and Genetic Therapy Inc. He served as Global Head of R&D for Baxter’s BioScience Division (2000 to 2003) and served as Global Head of Regulatory Affairs for Novartis Pharma from 1994 to 1996. Mike additionally serves on the Boards of Arrowhead Pharmaceuticals, AmpliPhi Biosciences and Gamida Cell. He also serves on the Editorial Advisory Board of the Journal Cell and Gene Therapy Insights.
Mike is an Adjunct Professor at the University of Colorado, School of Medicine, Gates Center for Regenerative Medicine and serves as Chair of the Translational Research board of the Houston Methodist Research Institute. Dr. Perry holds a B.Sc. in Physics from the University of Guelph in Canada, a Doctorate in Veterinary Medicine & Surgery from the Ontario Veterinary College, and a Ph.D. in Pharmacology from the University of Guelph. He is a graduate of the International Advanced Management Program at Harvard Business School.